This assumption was recently confirmed by demonstration of the anti-AD therapeutic efficacy of dupilumab, an anti–IL-4/IL-13 biologic drug targeting IL-4 receptor α (IL-4Rα), a common subunit of the IL-4 and IL-13 receptors [35,36]. The gene discussed is IL4R; the disease is Alzheimer disease.